New research explores how psilocybin, the compound found in "magic mushrooms," may improve both mood and motor symptoms in Parkinson's disease.
While psilocybin — the naturally occurring psychedelic
compound found in certain mushrooms — has already gained attention for its
potential in treating depression, anxiety, and PTSD, a new study now highlights
its promising effects on people living with Parkinson’s disease.
In a groundbreaking pilot study conducted by researchers at
the University of California, San Francisco (UCSF), psilocybin was shown
to help ease not only the mood disorders commonly seen in Parkinson’s patients
but also to improve aspects of their motor function. This marks a
significant development in the management of a disease that is notoriously
difficult to treat beyond symptom control.
The Study: Psychedelics and Parkinson’s
The small-scale pilot trial involved 12
participants — seven men and five women — all diagnosed with mild to
moderate Parkinson’s disease. These individuals often face dual challenges: the
well-known tremors, stiffness, and motor impairments associated with
Parkinson’s, as well as debilitating mood symptoms, such as anxiety and
depression.
Researchers administered an initial 10 mg dose of
psilocybin, followed by a higher 25 mg dose two weeks later.
Importantly, the treatment was well-tolerated, with no serious side effects
or worsening of symptoms.
But what truly stood out was the lasting impact:
participants experienced clinically significant improvements in their mood,
cognition, and motor function — effects that continued even after the
drug had left their systems.
A First in Neurodegenerative Disease Research
This is the first known clinical study to test a
psychedelic drug on patients with a neurodegenerative condition like
Parkinson’s.
“We are still in very early stages of this work, but this
first study went well beyond what we expected,” said Dr. Ellen Bradley,
Assistant Professor and Associate Director at UCSF’s Translational
Psychedelic Research Programme (TrPR). “Many people don't realise this, but
mood symptoms in Parkinson’s are linked to a faster physical decline,”
she explained. “And they are actually a stronger predictor of a patient’s
quality of life than motor symptoms.”
Understanding Parkinson’s Disease and the Challenge of Mood Symptoms
Parkinson’s disease is a progressive neurological
disorder caused by the degeneration of dopamine-producing neurons in the brain.
This leads to tremors, rigidity, and difficulty with balance
and movement.
While medications such as levodopa can relieve these
symptoms temporarily, there are no treatments currently available that
halt or reverse disease progression.
Mood symptoms — particularly depression and anxiety —
are extremely common in Parkinson’s, sometimes surfacing years before motor
symptoms even appear. Strikingly, many patients with no prior psychiatric
history find themselves facing mood disorders that don’t respond well to
conventional antidepressants.
Dr. Bradley and her team suggest that these mood changes may
be a direct result of the neurodegenerative process, rather than simply
a reaction to living with a chronic illness.
Although the study is small and exploratory, the early
results are encouraging. Psilocybin appears to be safe, well-tolerated,
and potentially transformative in the treatment of Parkinson’s — not just
for mood symptoms, but for motor function as well.
Researchers stress the need for larger,
placebo-controlled trials to further explore and validate the findings. But
for now, this study opens a hopeful new chapter in Parkinson’s care, showing
that a compound once considered fringe could hold key benefits for one of the
world’s most challenging diseases.
Disclaimer:
The health tips shared on
this blog are for informational purposes only and are not a substitute for
professional medical advice. Always consult a qualified healthcare provider
before making changes to your health routine. Content is based on publicly
available sources and edited for clarity.
.webp)
.webp)
.webp)
0 Comments